-DOCSTART- -X- O
Efficacy -X- _ O
of -X- _ O
antitumor -X- _ O
vaccination -X- _ O
depends -X- _ O
to -X- _ O
a -X- _ O
large -X- _ O
extent -X- _ O
on -X- _ O
antigen -X- _ O
targeting -X- _ O
to -X- _ O
dendritic -X- _ O
cells -X- _ O
( -X- _ O
DCs -X- _ O
) -X- _ O
. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
assessed -X- _ O
antitumor -X- _ O
immunity -X- _ O
induced -X- _ O
by -X- _ O
attenuated -X- _ B-Intervention
coronavirus -X- _ I-Intervention
vectors -X- _ I-Intervention
which -X- _ O
exclusively -X- _ O
target -X- _ O
DCs -X- _ O
in -X- _ O
vivo -X- _ O
and -X- _ O
express -X- _ O
either -X- _ O
lymphocyte- -X- _ O
or -X- _ O
DC-activating -X- _ O
cytokines -X- _ O
in -X- _ O
combination -X- _ O
with -X- _ O
a -X- _ O
GFP-tagged -X- _ O
model -X- _ O
antigen. -X- _ O
Tracking -X- _ O
of -X- _ O
in -X- _ O
vivo -X- _ O
transduced -X- _ O
DCs -X- _ O
revealed -X- _ O
that -X- _ O
vectors -X- _ O
encoding -X- _ O
for -X- _ O
Fms-like -X- _ O
tyrosine -X- _ O
kinase -X- _ O
3 -X- _ O
ligand -X- _ O
( -X- _ O
Flt3L -X- _ O
) -X- _ O
exhibited -X- _ O
a -X- _ O
higher -X- _ O
capacity -X- _ O
to -X- _ O
induce -X- _ O
DC -X- _ O
maturation -X- _ O
compared -X- _ O
to -X- _ O
vectors -X- _ B-Outcome
delivering -X- _ I-Outcome
IL-2 -X- _ I-Outcome
or -X- _ I-Outcome
IL-15. -X- _ I-Outcome
Moreover -X- _ I-Outcome
, -X- _ I-Outcome
Flt3L -X- _ I-Outcome
vectors -X- _ I-Outcome
more -X- _ I-Outcome
efficiently -X- _ I-Outcome
induced -X- _ I-Outcome
tumor-specific -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
, -X- _ I-Outcome
expanded -X- _ I-Outcome
the -X- _ I-Outcome
epitope -X- _ I-Outcome
repertoire -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
provided -X- _ I-Outcome
both -X- _ I-Outcome
prophylactic -X- _ I-Outcome
and -X- _ I-Outcome
therapeutic -X- _ I-Outcome
tumor -X- _ I-Outcome
immunity. -X- _ I-Outcome
In -X- _ I-Outcome
contrast -X- _ I-Outcome
, -X- _ I-Outcome
IL-2- -X- _ I-Outcome
or -X- _ I-Outcome
IL-15-encoding -X- _ I-Outcome
vectors -X- _ I-Outcome
showed -X- _ I-Outcome
a -X- _ I-Outcome
substantially -X- _ I-Outcome
lower -X- _ I-Outcome
efficacy -X- _ I-Outcome
in -X- _ I-Outcome
CD8 -X- _ I-Outcome
( -X- _ I-Outcome
+ -X- _ I-Outcome
) -X- _ I-Outcome
T -X- _ I-Outcome
cell -X- _ I-Outcome
priming -X- _ I-Outcome
and -X- _ I-Outcome
failed -X- _ I-Outcome
to -X- _ I-Outcome
protect -X- _ I-Outcome
the -X- _ I-Outcome
host -X- _ I-Outcome
once -X- _ I-Outcome
tumors -X- _ I-Outcome
had -X- _ I-Outcome
been -X- _ I-Outcome
established. -X- _ I-Outcome
Thus -X- _ O
, -X- _ O
specific -X- _ O
in -X- _ O
vivo -X- _ O
targeting -X- _ O
of -X- _ O
DCs -X- _ O
with -X- _ O
coronavirus -X- _ O
vectors -X- _ O
in -X- _ O
conjunction -X- _ O
with -X- _ O
appropriate -X- _ O
conditioning -X- _ O
of -X- _ O
the -X- _ O
microenvironment -X- _ O
through -X- _ O
Flt3L -X- _ O
represents -X- _ O
an -X- _ O
efficient -X- _ O
strategy -X- _ O
for -X- _ O
the -X- _ O
generation -X- _ O
of -X- _ O
therapeutic -X- _ O
antitumor -X- _ O
immunity -X- _ O
. -X- _ O

